Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
Galapagos NV - American Depositary Shares (GLPG)
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
glpg.com/company-overview
Company Research
Source: GlobeNewswire
Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025. The data show that the in vitro pharmacological profile of GLPG3667 suggests differentiation from other TYK2 inhibitors at their clinical dose regimens. Key findings from the study include: At exposure levels associated with its clinical dose of 150 mg once daily, GLPG3667 showed inhibition of the IFN-a, and IL-23 pathways, comparable to the expected inhibition for the currently approved TYK2 inhibitor at its clinical dose regimens, without a measurable impact on TYK2-independent pathways.Inhibition of the IL-12 pathway was more pronounced for GLPG3667 than for the
Show less
Read more
Impact Snapshot
Event Time:
GLPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLPG alerts
High impacting Galapagos NV - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GLPG
News
- Galapagos (NASDAQ:GLPG) is now covered by analysts at Sanford C. Bernstein. They set a "market perform" rating on the stock.MarketBeat
- Galapagos Receives Transparency Notifications from Bank of AmericaGlobeNewswire
- Galapagos (NASDAQ:GLPG) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GLPG&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
- Galapagos (NASDAQ:GLPG) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $32.00. They now have a "sector perform" rating on the stock.MarketBeat
- Galapagos Reports Nine Months 2025 Financial Results and Provides Business UpdateGlobeNewswire
GLPG
Earnings
- 11/5/25 - Miss
GLPG
Sec Filings
- 11/26/25 - Form 6-K
- 11/6/25 - Form 6-K
- 11/3/25 - Form 6-K
- GLPG's page on the SEC website